Product
Povorcitinib
Aliases
INCB054707
9 clinical trials
8 indications
Indication
Chronic Idiopathic UrticariaIndication
UrticariaIndication
AngioedemaIndication
PruritusIndication
Chronic Spontaneous UrticariaIndication
Hidradenitis SuppurativaIndication
VitiligoIndication
Healthy ParticipantsClinical trial
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous UrticariaStatus: Recruiting, Estimated PCD: 2025-03-07
Clinical trial
A Phase 3, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis SuppurativaStatus: Recruiting, Estimated PCD: 2026-12-26
Clinical trial
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental VitiligoStatus: Recruiting, Estimated PCD: 2026-05-18
Clinical trial
A Phase 1, Open-Label Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult FemalesStatus: Recruiting, Estimated PCD: 2024-06-07
Clinical trial
An Open-Label Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics When Administered Orally to Healthy Adult ParticipantsStatus: Recruiting, Estimated PCD: 2024-08-10
Clinical trial
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis SuppurativaStatus: Recruiting, Estimated PCD: 2025-03-11
Clinical trial
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental VitiligoStatus: Recruiting, Estimated PCD: 2026-05-09
Clinical trial
A Phase 1, Randomized, Partially Double-Blind, Placebo- and Positive-Controlled, Parallel Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy ParticipantsStatus: Not yet recruiting, Estimated PCD: 2024-09-08
Clinical trial
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis SuppurativaStatus: Recruiting, Estimated PCD: 2025-03-11